U.S. Food and Drug Administration Approves FoundationOne®Liquid CDx as the First Companion Diagnostic in the U.S. for WILSERDLY (giredestrant) in Combination with Everolimus for ER-Positive, HER2-Negative, ESR1-Mutated Advanced Breast Cancer

On November 16, 2026 Foundation Medicine, Inc., a global, patient-focused precision medicine company, reported that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOneLiquid CDx to be used as a companion diagnostic (CDx) for WILSERDLY (giredestrant) in combination with everolimus. FoundationOne Liquid CDx is the first FDA-approved companion diagnostic to identify patients who may be eligible for WILSERDLY in combination with everolimus and is covered by Medicare for patients with advanced cancer. This approval further establishes FoundationOne Liquid CDx as a key liquid biopsy test for advanced breast cancer, providing healthcare providers with clinically relevant genomic biomarker data from a single test.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

WILSERDLY is an estrogen receptor antagonist indicated in combination with everolimus for the treatment of adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer, as detected by an FDA-authorized test, whose disease has recurred during or after completion of endocrine-based adjuvant therapy, or has progressed on at least one endocrine-based regimen in the metastatic setting.

Foundation Medicine has nine FDA-approved CDx indications for breast cancer, the most of any comprehensive genomic profiling (CGP) company.1 Foundation Medicine offers FDA-approved tissue- and liquid-based CGP tests and helps biopharmaceutical partners streamline clinical development, devise regulatory strategy and maximize patients’ access to novel therapies. This is supported by Foundation Medicine’s position as the global leader in approved CDx indications, with more than 100 approved CDx indications.2

ER-positive, HER2-negative breast cancer accounts for approximately 70% of breast cancer cases.3 Acquired ESR1 mutations can cause resistance to endocrine therapies, particularly in the post-cyclin-dependent kinase (CDK) inhibitor setting, increasing the risk of disease progression and leading to poor outcomes.3,4 In the post-CDK inhibitor setting, up to 40% of people with ER-positive, HER2-negative disease have ESR1 mutations.5,6

"Breast cancer can mutate and become resistant to early treatments, making biomarker testing at recurrence critical," said Vera Grossmann, interim chief executive officer and chief operating officer at Foundation Medicine. "FoundationOne Liquid CDx has the sensitivity necessary to detect ESR1, helping identify patients who may benefit the most from Genentech’s next-generation SERD combination therapy."

"Learning their current treatment for metastatic breast cancer is no longer working causes fear and uncertainty for patients and their loved ones," said Jean A. Sachs, MSS, MLSP, chief executive officer at Living Beyond Breast Cancer. "Given the prevalence of metastatic breast cancer patients whose cancer acquires an ESR1 mutation, we are excited to see a new therapy option and a high-quality companion diagnostic approved to help identify patients who may be a good fit for this treatment."

(Press release, Foundation Medicine, NOV 16, 2026, View Source [SID1234674839])